We therefore examined whether genetic or pharmacologic inhibition of G9a impacts breast cancer cell motility in a poorly metastatic estrogen receptor positive (ER+) cell line (MCF7), and a highly metastatic, estrogen receptor negative (ER-) (MDA-MB-231) cell line. This evidence concerns the gene EHMT2 and breast carcinoma.